Hematogenous thrombophilia as a cause of thrombosis of various localizations. Efficiency of secondary prevention of thromboformation
https://doi.org/10.24412/2311-5068-2024-12-2-5
Abstract
This study examined the prevalence of hematogenous thrombophilia markers in patients with various types of thrombotic complications, heredity for pathological thrombus formation, and assessed the effectiveness of dabigatran, rivaroxaban, and apixaban for secondary thromboprophylaxis in such patients. The most common thrombotic complications in patients with hematogenous thrombophilia were: lower extremity vein thrombosis and pulmonary embolism. In most cases (77%), there was a combined form of hematogenous thrombophilia, when a combination of two or more thrombogenic risk factors was registered. The most frequently diagnosed mutations were F5 Leiden, MTHFR in combination with hyperhomocysteinemia, PAI-1 in homozygous form, primary antiphospholipid syndrome and prothrombin mutation F2 G20210A, less common were deficiency of antithrombin III, protein C and protein S. Heredity of hematogenous thrombophilia was detected in 70% of patients. For secondary prevention of thrombus formation in hematogenous thrombophilia, dabigatran, rivaroxaban, apixaban are equally effective and safe.
About the Authors
Yu. M. Demenko
Amur State Medical Academy of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Yuliya M. Demenko
Blagoveshchensk
V. V. Voitsehovsky
Amur State Medical Academy of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Valery V. Voitsehovsky
Blagoveshchensk
S. Р. Alatartseva
Amur State Medical Academy of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Sofiya P. Alatartseva
Blagoveshchensk
S. A. Artymuk
Amur State Medical Academy of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Sofiya A. Artymuk
Blagoveshchensk
N. A. Bogachev
Amur State Medical Academy of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Nikita A. Bogachev
Blagoveshchensk
References
1. World Health Organization: Inherited Thrombophilia: Report of a Joint WHO. International Society of Thrombosis and Hemostasis (ISTH) Meeting. Geneva: World Health Organization, 1995. PMID: 9277004.
2. Barkagan ZS. Prethrombotic conditions and thrombophilia : Handbook of hematology. Vorobyov AI, editor. Moscow: Newdiamed,2005;3;133–147. (In Russ).
3. Momot AP, Taranenko IA, Tsyvkina LP. Evolution of ideas about thrombophilia and its role in human reproduction. Obstetrics and Gynecology, 2013;2;4–9. (In Russ.).
4. Douketis J.D., Spyropoulos A.C., Spencer F.A., Mayr M., Jaffer A.K., Eckman M.H., Dunn, A.S., Kunz R. American College of Chest Physicians. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (2, Suppl.): e326S-50S. https://doi.org/10.1378/CHEST.11-2298.
5. Prandoni P. Acquired risk factors for venous thromboembolism in medical patients. Hematology. Am. Soc. Hematol Educ. Program. 2005: 458-61. https://doi.org/10.1182/asheducation-2005.1.458.
6. Voitsehovsky VV, Landyshev YuS, Grigorenko AA, Tkacheva SI, Kalenbet LI, Goborov ND. Violation of endobronchial microhemocirculation in patients with multiple myeloma. Far Eastern Medical Journal, 2010; 2;30–33. (In Russ.).
7. Landyshev YuS, Voitsehovsky VV, Shcherban NA, Lazutkina EL, Kravets ES, Danilenko SA, Gladun EA, Tkacheva SI, Kalenbet LI. Endobronchial microhemocirculation in diseases of internal organs. Far Eastern Medical Journal;2012;1;6–11. (In Russ.).
8. Bates S.M., Greer I., Pabinger I. Sofaer S., Hirsh J. Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008;133(6);844–886. https://doi.org/10.1378/chest.08-0761
9. Momot AP. Modern methods for recognizing the state of thrombotic readiness. Barnaul: Publishing House of Altai State University, 2011. (In Russ.). ISBN 978-5-7904-1176-2.
10. Subbotovskaya AI, Tsvetovskaya GA, Slepukhina AA, Lifshits GI. Polymorphism of the plasminogen activator inhibitor gene in assessing the risk of developing thrombosis of various localizations (pilot study). Russian Journal of Cardiology, 2015;10;50–53. (In Russ.).
11. Rabinovich A, Cohen JM, Kahn SR. The predictive value of markers of fibrinolysis and endothelial dysfunction in the post thrombotic syndrome. A systematic review. Thromb Haemost. 2014;111(6):1031–1040. https://doi.org/10.1160/TH13-11-0931
Review
For citations:
Demenko Yu.M., Voitsehovsky V.V., Alatartseva S.Р., Artymuk S.A., Bogachev N.A. Hematogenous thrombophilia as a cause of thrombosis of various localizations. Efficiency of secondary prevention of thromboformation. Amur Medical Journal. 2024;12(2):5-9. (In Russ.) https://doi.org/10.24412/2311-5068-2024-12-2-5
Views:
20
JATS XML
Email this article 